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Abstract
We demonstrated the  value of  multiparameter  flowcytometry in  detecting human
tumor cells of breast cancer in peripheral blood, which had a sensitivity limit of 10-5 and
higher specificity compares with real‐time polymerase chain reaction (RT‐PCR). It was
also found that circulating tumor cell (CTC) number was related with TNM stage,
metastasis and the overall survival of patients. CTC level was one of the important
factors for patients’ prognosis. At the same time, we also verified the circulating tumor
stem cell (CTSC) was connected with TNM stage by multiparameter cytometry. The
detection of CTC and CTSC by multiparameter flowcytometry may be used to diagnose
disease at early stage to guide clinical therapy or to predict prognosis. Multiparame‐
ter flowcytometry has the potential to be a valuable tool for prognosis assessment
among patients with breast cancer in clinical situation in China.
Keywords: circulating tumor cells (CTC), circulating tumor stem cells (CTSC), epithe‐
lial‐mesenchymal transiton (EMT), multiparameter flow cytometry, subtraction en‐
richment
1. Introduction
MERGEFORMAT breast cancer is the most common cancer in women in developed coun‐
tries. In developing countries, such as China, the incidence of breast cancer is currently increasing,
particularly in larger cities [1]. It is considered to be a systemeic disease as tumor cell dissemi‐
nation at early stage. The major problem of recurrence and death is due to the persistence of
minimal residual disease [2]. There is great interest in finding biomarkers in peripheral blood,
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which can be sampled at any stage of the disease. Then, the detection of CTCs for monitoring
therapy was highly investigated in breast cancer. Circulating cells with the characteristics of
tumor cells can be identified in the peripheral blood that is known as circulating tumor cells
(CTCs) in many patients with solid tumors of epithelial origin. These cells are present both in
patients with metastasis and in those whose tumors are localized [3]. Tumor cells shed into the
circulation intermittently which was corresponding with microinvasive events. The first phase
of metastatic consists of lessens of tumor cell adhesion, induction of tumor cell motility and local
tumor cell invasion [4]. These steps are followed by either spread to circulation in peripheral
blood or regional lymph nodes, and locating in secondary organs [5]. Some of these cells generate
metastases eventually that can arise many years after therapy of the primary tumor at earlier
phase [2]. CTCs also may be related to a half‐life probably 1–2.4 h, which means it cannot always
exist in circulating [6]. Some authors argued that these cells were predominantly in G0 phase
and thus are not replicating [7]; however, they did not exclude the existence that the prolifera‐
tion of CTCs can occur, although it was a rare event. Considering the half‐life of CTCs, the
presence of CTCs in the blood could be maintained by a balance between replication and cell
death. While apoptosis contributed to a high rate of circulating tumor cells, only a small part of
the cells can adhere in second organs through blood vessels that were named as circulating
tumor stem cells (CTSCs) [8].
CTCs can be selected with a monoclonal antibody directed against CD45 for negative selection
of leukocytes [9–11]. And from this cluster cells, EpCAM (epithelial‐cell adhesion molecule)
and cytokeratin‐8 (CK‐8), CK‐18, CK‐19 (CK‐8, CK‐18, CK‐19 phycoerythrin staining)‐positive
cells are the target cells, which were known as the marker of epithelial cells. The characteri‐
zation of CTCs presents a very hot topic in breast cancer research nowadays [12]. It helped to
identify diagnosis and provide individual therapies according to the characterization of CTCs
[12–14]. The characterization of CTSCs contributed to the identification and targeted therapy
in breast cancer in the near future [15]. Molecularly targeted cancer therapies contributed great
help which according to the characterization of CTCs especially on patients whose tumors
have a particular mutation [16]. Some of the biological properties and the molecular charac‐
teristics of CTCs were connected to CTSCs and the genomic profiles have been completed [15].
Following that, the CD44‐positive CD24‐negative cells with their tumor‐initiating ability had
been considered as CTSCs [17]. Hence, from CTC, CD44‐positive cell and CD24‐negative cell
are CTSCs. Molecular characterization of CTCs, which is important for the identification of
diagnostically and therapeutically relevant for individual therapies, it is difficult to address
since they are very rare and the amount of available sample is very limited. Given the
properties of the metastatic CTCs, there should be some opportunities for early identification
and therapeutic targeting in breast cancer.
Some immunologic procedures, such as immunohistochemistry‐based methods and reverse
transcriptase polymerase chain reaction (RT‐PCR), have been used to detect CTCs in past time
[18–22]. However, current methods of detection do not seem to be sensitive or specific enough
to apply in clinical [23–25]. Nowadays, we demonstrate the advent of the flow cytometry in
the detection of CTCs, which makes a good balance of sensitivity and specificity. In addition,
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the procedure of the method was simple and the cost was lower than immunologic technology,
which made it possible to apply in clinical.
2. Methods
2.1. Patients
We investigated 45 patients with breast cancer in the Union Hospital in Wuhan during
September 2006 and June 2008 with three normal people as negative control. Twenty‐five
patients had overt metastasis and 20 patients had no sign of overt metastasis. The character‐
All CTC < 5 (n = 27) CTC ≥ 5 (n = 18) P‐valuea
n % n % n %
Age, years
 Minimum 32 – 32 – 37 – 0.640
 Median 50 – 49 – 51 –
 Maximum 74 – 72 – 74 –
TNM stage
 I 5 13.3 5 100.0 0 0.0 0.033
 II 4 8.9 4 100.0 0 0.0
 III 11 24.4 7 63.6 4 36.4
 IV 25 55.6 11 41.7 14 58.3
Primary tumor sites
 Left breast 24 53.3 14 58.3 10 41.7 0.807
 Right breast 21 46.7 13 61.9 8 38.1
Clinical pathology
 Infiltrating ducta 28 62.2 17 60.7 11 39.3 0.921
 Papillary 10 22.2 6 60.0 4 40.0
 Squamous celled 4 8.9 2 50.0 2 50.0
 Mucous cancer 1 2.2 1 100.0 0 0.0
 Medullary 2 4.4 1 50.0 1 50.0
Diameter of tumor
 ≤2.0 cm 13 28.9 9 615 4 30.7 0.522
 2.0–5.0 cm 27 60.0 16 59.3 11 40.7
 >5.0 cm 5 11.1 2 40.0 3 60.0
ALND
 Yes 35 77.8 19 54.3 16 45.7 0.143
 No 10 22.2 8 80.0 2 20.0
Metastasis
 Yes 25 55.6 10 40.0 15 60.0 0.002
 No 20 44.4 17 85.0 3 15.0
ALND, axillary lymph node dissection.
Table 1. Patient characteristics.
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istics of the patients are shown in Table 1, including mean age, TNM phase, histopathology,
lymph node status, metastasis and so on. All these patients were incipient and were treated
by systemic therapy, including 12 patients cured by cytokine‐induced killer cells therapy (CIK).
And all the patients were drawn blood for the detection of CTCs.
2.2. Cell line
Carcinoma cell line SKBR‐3 (breast) was used to estimate the sensitivity and specificity of the
flow cytometry, which was maintained in RPMI 1640 plus 10% fetal calf serum.
2.3. Antibodies
Antibodies, which were used for multiparameter flow cytometry, were as follows: anti‐CD45‐
PerCP, anti‐CD44‐APC (allophycocyanin, clone G44‐26, catalog number 559942) and anti‐
CD24‐FITC (fluorescein isothiocyanate, clone ML5, catalog number 555427) were from Becton
Dickison Crop., USA. Ep‐CAM (epithelial‐cell adhesion molecule) and CK‐8, CK‐18, CK‐19
(CK‐8, CK‐18, CK‐19 phycoerythrin staining) were from Abcam, USA.
2.4. Preparation of samples
Every patient with breast cancer drew 20 ml blood for CTCs detection and three healthy
volunteers. The blood of healthy volunteers was treated as negative control. About 5 ml blood
was discarded to avoid contamination with skin cells as previously described [26]. We
separated mononucleocytes from 15 ml blood by Ficoll‐Paque (Haoyang Biological Production
Limited Company, Tianjin, China) for 20 min with 1800 × g at 25°C. One half of the mononu‐
clear cells was resuspended in phosphate‐buffered saline (PBS) for multiparameter flow
cytometry on the account of at least 2–3 × 106 cells for each sample and the other half was kept
in Trizol reagent (Invitrogen, UK) at -70°C until RNA extraction for RT‐PCR.
2.5. Flow cytometry
Mononucleocytes were enriched and washed twice with PBS and then labelled antibodies that
target white cell antigens and epithelial cell antigens (CD45‐, Ep‐CAM+, CK‐8, CK‐18, CK‐
19+), kept in dark at 4°C for 30 min. We added 20 µl monoclonal antibodies for each sample.
Cell pellets were resuspended in 250 µl PBS and enumerated by FACS Caliber™ (Becton
Dickison Crop., USA) at last.
SKBR‐3 breast cancer cells were used to evaluate the sensitivity of the flow cytometry (tumor
cells recovery). Tumor cells were resuspended and counted. 1, 10, 50, 500 cells were spiked,
respectively, into 7.5 ml of blood from healthy person. And then, it was processed as described
as earlier and control the preparation for the same volume of the cell suspension and cells were
counted to accurately estimate the number of cells spiked into the blood. The average number
of Ep‐CAM and CK‐8, CK‐18, CK‐19 positive cells on FACS Caliber™ was used to calculate
the cells recovery.
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The mononuclear cells (MNCs) for FCM were incubated with monoclonal antibodies: anti‐
CD45‐PerCP, anti‐EPCAM‐PE, anti‐CD44‐APC and anti‐CD24‐FITC. About 20 µl of each
antibody was needed, and the condition was 4°C for 30 min away from light. Then, the MNCs
were washed two times. Finally, cells were resuspended with PBS and analyzed on FACS
CaliburTM (BD Bio) using Cell Quest software (BD Bio).
2.6. RT‐PCR
We extract RNA with 1 ml trizol from the mononucleocytes, which were separated from 7.5
ml blood and then kept at -70°C. Add 0.2 ml chloroform and then centrifuge the sample at
12,000 × g for 15 min at 4°C. The intact RNA, which was contained in the supernatants, was
removed into a new tube. RNA was dissolved in 10 µl RNase‐free water after precipitating
RNA with isopropyl alcohol and washing with 75% ethanol. Then, RNA was transcribed to
cDNA by a reverse transcriptase in a total 10 µl RT reaction solution, which was contained of
2 µl 5x Reverse Transcriptase Buffer, 1 µl dNTP (10 mM each), 0.25 µl RNase inhibitor (10 U),
1 µl oligo (dT)15 primer (25 pmol), 5.25 µl RNase‐free water containing RNA (>0.5 µg), 0.5 µl
avian myeloblastosis virus (AMV) reverse transcriptase (5U) (TaKaRa, China). The resulting
cDNA was subjected to PCR amplification. PCR was composed of 2 µl cDNA, 10 µl Mix, 2 µl
primer of EpCAM, 6 µl H2O in a total volume of 20 µl. The primer of EpCAM was as follows:
5’‐GGACCTGACAGTAAATGGGGAAC‐3’; 5’‐CTCTTCTTTCTGGAAATAACCAGCAC‐3’
[18]. GAPDH mRNA primer detail was as follows: 5’‐TGCACCACCAACTGCTTAGC‐3’; 5’‐
GGAGGCAGGGATGATGTTCT‐3’ which was designed by Primer 5.0. The reaction condition
was 95°C for 2 min to activate Taq DNA polymerase and it finally elongated 72°C for 7 min
with 35 cycles. We detected the PCR products by ethidium bromide staining on a 1% agarose
gel.
2.7. Statistical analysis
Correlation, regression analysis and a Mann‐Whitney rank sum test were performed on
titration experiments. Chi‐square test was used to compare across CTC groups. Overall
survival was performed to describe the condition of CTCs and prognosis and was estimated
by the Kaplan‐Meier. Comparison of groups used the log‐rank test. All statistical tests were
two‐sided, and P values < 0.05 were considered statistically significant. Analyses above were
performed by using the SPSS 13.0.
3. Results
3.1. Sensitivity and specificity
3.1.1. Sensitivity
It is demonstrated that the sensitivity of the method of CTCs detection by using multiparameter
flow cytometry was 0.001%, or 10-5, according to the serial dilutions test, which is shown in
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Figure 1a–d. It was highly reproducible on recovery and linearity across three separate
experiments (Figure 1e). The recovery of the tumor events was quite correlated with the tumor
events expected based on the serial dilutions (R2 = 0.997). The recovery of the tumor cells was
not significantly different from the tumor cells expected according to the serial dilutions (P > 
0.6, Mann‐Whitney rank sum test).
3.1.2. Specificity
The detection of CTCs by multiparameter flow cytometry contributed a higher specificity
compared with RT‐PCR. We detected the expression of Ep‐CAM in three typical advanced
breast cancer (ABC) patient (CTCs ≥ 5) and three limited breast cancer (LBC) patients (CTCs 
< 5). The result showed that the expression of Ep‐CAM was positive for both patients with
ABC and LBC as shown in Figure 2. It was hard to distinguish ABC with LBC by RT‐PCR,
while the flow cytometry could distinguish them obviously and quantitatively.
Figure 1. The ability to detect human tumor cells SKBR‐3 cells in normal blood by cytomentry is titratable down to a
sensitivity of 0.001%.Human tumor cells concentration was normalized adding to the leukocyte count, and serial dilu‐
tions (0.0001, 0.001%, 0.005%, 0.05%) using normal mononucleocytes as the diluent. Samples were lysed, incubated
with anti‐CD45‐PerCP (20ul), EpCAM (20ul) and Cytokeratin8, 18, 19 (20ul) at 4°C for 30 minutes, and resuspended in
250ul PBS before multiparameter flow cytometric analysis. For samples with normal blood cells, up to 1000,000 total
events were collected. Events that fell within up right region were counted as meeting the criteria for SKBR‐3 tumor
cells (CD45‐EpCAM+CK+). Representative SKBR‐3 cells are shown for (a) 0.0001% (b) 0.001% (c) 0.005%, (d) 0.05%. (e)
Correlation and regression analysis of recovered versus expected number of positive tumor events at dilutions signifi‐
cant at the 0.01 level (2‐tailed, R2 =0.997, three separate experiments.). The percentage of tumor cells recovered was not
significantly different from the percentage of tumor cells expected based on the serial dilutions (P>0.6, Mann‐Whitney
rank sum test).
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Figure 2. RT‐PCR assay for EpCAM mRNA (a) and GAPDH mRNA (b). 1. DNA ladder, 2. negative control (H2O), 3.
positive control (SKBR‐3 cells), 4.5.6. ABC samples, 7.8.9. LBC samples. All were positive. Size of EpCAM and GAPDH
is 186bp and 177bp, respectively.
Patient no. EPCAM (10-5) CD44
CTC <50 CTC≥50 CTSC negative CTSC positive
1 24.41 97.66 0.38 0.41
2 2.99 72.99 0.36 0.62
3 4.96 48.81 0.48 0.96
4 3.29 1.66 0.92 0.82
5 1.19 3.41 0.75 0.63
6 2.99 24.41 0.66 0.46
7 2.28 24.39 1.04 0.84
8 6.31 48.85 0.44 0.57
9 5.17 39.39 4.20 0.17
10 48.83 5.50 1.01 0.34
11 69.05 48.88 1.17 0.41
12 30.27 2.81 0.84 1.43
13 4.38 11.08 0.06 3.39
14 41.92 6.10 0.63 0.99
15 10.05 5.98 0.58 0.49
16 75.56 0.43 0.47
17 2.62 0.50
18 29.24
Control 0.14 ± 0.02 0.59 ± 0.10
Table 2. Analysis of EPCAM and CD44 gene expression in patients with BC.
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We also compared breast cancer (BC) patients with healthy volunteers by QRT‐PCR. The
expression of Ep‐CAM was increased statistically higher in patients with BC (24.29 ± 44.10 vs.
0.14 ± 0.02 × 10-5, P = 0.000) than in healthy volunteers, which was shown in Table 2 and it was
calculated by 2-Δt method. However, there were no obvious differences between BC and health
on the expression of CD44. Therefore, we confirmed that Ep‐CAM and CD44 cannot be
identified by QRT‐PCR but can be identified by multiparameter flow cytometry.
3.2. Patient characteristics
Forty‐five patients were identified and included in this analysis (detail is shown in Table 1);
27 (60.0%) patients had CTCs levels <5 and 18 (40.0%) patients had CTCs levels ≥5, respectively.
The age of all the 45 patients ranged from 32 to 74, while the median age of CTCs levels <5
group was 49 years and the median age of CTCs ≥5 was 51 years. There were 25 (55.6%) patients
in metastasis including 15 (33.3%) patients had CTCs ≥5. At the same time, there were 20
(44.4%) patients with no metastasis including 17 patients had CTCs <5. It showed that there
was statistically significantly differences (P = 0.002) on CTCs level between the metastasis
group and no metastasis group by chi‐square test analyses. And the statistical differences of
CTCs level also exist in different TNM stage (P = 0.033).
Figure 3. Kaplan‐Meier Plots of overall survival are shown for all patients during the follow‐up. 27 patients in CTCs <5
group and the median survival is estimated to be 95 weeks. 18 patients in CTCs≥5 group and the median survival is
65.5 weeks. P value is 2‐tailed. Logrank indicates the P value, p=0.004.
3.3. Survival analysis
There were 17 (37.8%) patients who died during the follow‐up period including 11 (24.5%)
patients in CTCs ≥5 group. The median survival among CTCs <5 group was 95 weeks (standard
deviation, 18.67 weeks) and the median survival among CTCs ≥5 was 65.5 weeks (standard
deviation, 30.0 weeks). Axillary lymph node dissection (ALND) had correlation with CTCs
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level (P = 0.143) and 45.7% ALND patients got CTCs ≥5. During the follow‐up, 11 (24.4%)
patients got lost contact with seven (15.6%) in < 5 CTCs and four (8.9%) in ≥ five CTCs group.
The results of the patients survival are shown in Figure 3 by Kaplan‐Meier with logrank
P=0.004 and Breslow P=0.003, which confirm that the survival of CTCs < 5 and CTCs ≥ 5 group
were different statistically. And the overall survival (OS) of CTCs < 5 group was higher than
CTCs ≥ 5 group.
Variables bj Sbj P expbj 95.0% CI for expbj
Lower Upper
Age 0.101 0.031 0.001 1.107 1.042 1.176
CTCs 1.204 0.589 0.041 3.333 1.050 10.581
ALND -1.813 1.111 0.103 0.163 0.018 1.439
Diameter 1.029 0.822 0.211 2.799 .558 14.025
Metastasis 2.825 0.910 0.002 16.855 2.834 100.237
Table 3. Cox regression analysis results.
In addition, we found that the prognosis of patients with breast cancer was statistical signifi‐
cant in CTCs level (P = 0.041), age (P = 0.001) and metastasis (P = 0.002) base on the Cox
regression analysis for the follow‐up in 45 patients as shown in Table 3.
3.4. Circulating tumor stem cells
We also analyzed the expression of CTSCs and the characteristic of clinical data was shown in
Table 4. There were 21 patients had at least one CTSCs expression among 45 patients with
breast cancer. The CTSCs level in different TNM stages was statistically different (P = 0.020).
It was obvious that stage III and IV patients contributed more CTSCs expression than stage I
and II.
Patient characteristics Number (%) CTC (%) P‐value CTSC (%) P‐value
<50 ≥50 Negative Positive
Age (years) 0.247 0.168
≤45 24 (53.3) 12 (50) 12 (50) 10 (41.7) 14 (58.3)
>45 21 (46.7) 15 (71.4) 6 (28.6) 14 (66.7) 7 (33.3)
TNM stage 0.0272* 0.0202*
0 4 (8.9) 4 (100.0) 0 (0.0) 4 (100.0) 0 (0.0)
I 6 (13.3) 6 (100.0) 0 (0.0) 4 (66.7) 2 (33.3)
II 14 (31.1) 8 (57.1) 6 (42.9) 10 (71.4) 4 (28.6)
III 19 (42.2) 9 (47.4) 10 (52.6) 6 (31.6) 13 (68.4)
IV 2 (4.4) 0 (0.0) 2 (100.0) 0 (0.0) 2 (100.0)
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Patient characteristics Number (%) CTC (%) P‐value CTSC (%) P‐value
<50 ≥50 Negative Positive
Tumor size 0.155 0.165
Tis 4 (8.9) 4 (100.0) 0 (0.0) 4 (100.0) 0 (0.0)
T1 10 (22.2) 7 (70.0) 3 (30.0) 7 (70.0) 4 (30.0)
T2 20 (44.4) 12 (60.0) 8 (40.0) 8 (45.0) 11 (55.0)
T3 5 (11.1) 1 (20.0) 4 (80.0) 2 (40.0) 3 (60.0)
T4 6 (13.3) 3 (50.0) 3 (50.0) 2 (33.3) 4 (66.7)
RLNM 0.075 0.0012*
0 24 (53.3) 16 (66.7) 8 (33.3) 19 (79.2) 5 (20.8)
1–3 9 (20.0) 7 (77.8) 2 (22.2) 3 (33.3) 6 (66.7)
>3 12 (26.7) 4 (33.3) 8 (66.7) 2 (16.7) 10 (83.3)
Clinical pathology 0.264 0.098
CIS 4 (8.9) 4 (100.0) 0 (0.0) 4 (100.0) 0 (0.0)
Infiltrating duct 36 (80.0) 21 (58.3) 15 (41.7) 16 (44.4) 20 (55.6)
Mucous 2 (4.4) 1 (50.0) 1 (50.0) 2 (100.0) 0 (0.0)
Infiltrating lobular 1 (2.2) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0)
Medullar 1 (2.2) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0)
Papillary 1 (2.2) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Histology stagea 0.002* 0.919
I 4 (10.5) 3 (75.0) 1 (25.0) 2 (50.0) 2 (50.0)
II 17 (44.7) 14 (82.4) 3 (17.6) 8 (47.1) 9 (52.9)
III 17 (44.7) 4 (23.5) 13 (76.5) 7 (41.2) 10 (58.8)
ER 0.0182* 0.482
- 13 (28.9) 4 (30.8) 9 (69.2) 8 (61.5) 5 (38.5)
+ 32 (71.1) 23 (71.9) 9 (28.1) 16 (50.0) 16 (50.0)
PR 0.0052* 0.771
- 16 (35.6) 5 (31.3) 11 (68.7) 9 (56.3) 7 (43.7)
+ 29 (64.4) 22 (75.9) 7 (24.1) 15 (51.7) 14 (48.3)
Her‐2 0.405 0.262
1+ 14 (31.1) 10 (71.4) 4 (28.6) 10 (71.4) 4 (28.6)
2+ 18 (40.0) 11 (61.1) 7 (38.9) 8 (44.4) 10 (55.6)
3+ 13 (28.9) 6 (46.2) 7 (53.8) 6 (46.2) 7 (53.8)
CIS, carcinoma in situ.
aThere are missing values.
*P<0.05.
Table 4. Patient characteristics in different CTC and CTSC levels.
Tumor Metastasis204
The CTSC positive was also related with RLNM status (RLNM 0, 20.8%; RLNM 1–2, 66.7%;
RLNM >3, 83.3%) and the P‐value was 0.001. There were no statistical differences in regard to
age, diameter of tumor, clinical pathology, histology stage, ER status, PR status and Her‐2
status in different CTSC groups.
3.5. Percentages of CD45‐cells, CTCs, CTSCs and their clinical relevance
The expression of CD45, CTCs and CTSCs was further explored in different BC groups
(Table 5). The expression of CTSCs on CD45‐C showed a rising tendency in different TNM
stage (P = 0.034) and also in different RLNM status (P = 0.001).
Patient characteristics CD45-/MNC (%) CTC/CD45- (%) CTSC/CD45- (%) CTSC/CTC (%)
TNM stage a a *c c
0 2.01 ± 1.08 0.11 ± 0.12 0.00 ± 0.00 0.00 ± 0.00
I 1.29 ± 0.92 0.24 ± 0.25 0.03 ± 0.05 5.38 ± 11.46
II 2.72 ± 5.26 0.42 ± 0.51 0.06 ± 0.14 3.72 ± 7.63
III 2.52 ± 2.22 0.48 ± 0.69 0.10 ± 0.09 2.71 ± 3.78
IV 1.94 ± 0.88 1.00 ± 0.53 0.29 ± 0.35 5.45 ± 2.05
RLNM a c *c a
0 2.43 ± 4.01 0.28 ± 0.28 0.02 ± 0.05 2.49 ± 6.30
1–3 1.99 ± 1.66 0.25 ± 0.21 0.14 ± 0.17 4.77 ± 8.89
≥4 2.46 ± 2.59 0.83 ± 0.90 0.14 ± 0.15 3.67 ± 4.05
Clinical pathology c *a a a
Carcinoma in situ 2.01 ± 1.08 0.12 ± 0.12 0.00 ± 0.00 0.00 ± 0.00
Infiltrating duct 2.00 ± 1.79 0.37 ± 0.38 0.09 ± 0.14 4.07 ± 6.86
Mucous 11.57 ± 13.04 0.21 ± 0.30 0.00 ± 0.00 0.00 ± 0.00
Infiltrating lobular 1.13 ± 0.00 0.24 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Medullar 0.84 ± 0.00 1.34 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Papillary 0.47 ± 0.00 3.14 ± 0.00 0.13 ± 0.00 0.42 ± 0.00
Histology stage a a a c
I 2.56 ± 1.78 0.18 ± 0.16 0.03 ± 0.04 7.43 ± 14.10
II 1.38 ± 0.85 0.34 ± 0.41 0.10 ± 0.14 4.32 ± 7.15
III 2.33 ± 2.29 0.66 ± 0.76 0.10 ± 0.14 2.56 ± 3.31
ER b b b b
- 1.55 ± 0.78 0.52 ± 0.41 0.08 ± 0.16 2.10 ± 3.03
+ 2.67 ± 3.80 0.38 ± 0.61 0.07 ± 0.11 3.73 ± 7.24
PR b b b b
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Patient characteristics CD45-/MNC (%) CTC/CD45- (%) CTSC/CD45- (%) CTSC/CTC (%)
TNM stage a a *c c
- 2.09 ± 2.15 0.51 ± 0.42 0.08 ± 0.15 2.37 ± 3.37
+ 2.49 ± 3.76 0.37 ± 0.63 0.07 ± 0.11 3.76 ± 7.49
Her‐2 a a c a
1+ 2.93 ± 5.20 0.33 ± 0.47 0.03 ± 0.05 3.21 ± 7.63
2+ 2.45 ± 2.32 0.36 ± 0.35 0.09 ± 0.14 1.68 ± 2.80
3+ 1.57 ± 0.99 0.61 ± 0.83 0.11 ± 0.15 5.51 ± 7.96
*P < 0.05.
aANOVA test.
bStudent's t‐test.
cKruskal‐Wallis test.
Table 5. Percentage of CD45- cells, CTC and CTSC, and their clinical relevance.
The percentages of CTCs on CD45‐C with TNM and histology stage increasing. In addition,
we found that the percentage of CTCs on CD45‐C in ER- and PR- groups was higher than that
in ER+ and PR+ groups. And so was on CTSCs. Above all, we found the relationship between
the percentage of CTC on CD45‐C and clinical pathology. Then, it was good for evaluate TNM
stage and RLNM status according to the percentage of CTSC on CD45‐C.
Therefore, multiparameter flow cytometry technique is capable enough to identify patients
with breast cancer and assess the progression of disease.
4. Discussion
4.1. The significances of CTCs in breast cancer
The detection of CTCs by using multiparameter flow cytometry relied on the epithelial‐specific
marker, which was expressed on epithelial cells but not on leukocytes [2, 27, 28]. Some of the
CTCs that had higher metastatic potential may lose the expression of epithelial‐specific
markers during the migration process [29–31]. We also target another epithelial‐specific
marker—Ep‐CAM (epithelial‐cell adhesion molecule) to avoid possible false negative [32]. In
order to detect the tumor cells that come from epithelium tissue, a monoclonal antibody
directed against CD45 for negative selection of leukocytes [9–11]. Therefore, we targeted the
dual‐positive cells (CD45‐EpCAM+CK+) as a surrogate marker for CTCs. And the serial dilution
test was demonstrated to confirm the sensitivity of the assay by adding SKBR‐3 into healthy
sample. At the same time, we also verified the higher specificity of multiparameter flow
cytometry by comparing with RT‐PCR, although RT‐PCR had a higher sensitivity [10, 11, 33,
34]. However, the detection of CTCs by nucleic acid techniques may overestimate the sensi‐
tivity, which resulted from the membrane fragments or nucleic acid of markers because of the
crack of tumor cells in circle. CTC detection should be performed on cell level. On the other
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hand, we came out the result that RT‐PCR could not identify the ABC patient (CTCs ≥ 5) from
LBC patients (CTCs < 5) because of the high sensitivity of RT‐PCR technology. We chose the
multiparameter flow cytometry as the way to detect CTCs under considering the balance of
sensitivity and specificity. It was important to discard the first few milliliters of sampled blood
to make sure that there was no false positive because of the epithelial cell fell off from the skin
when punctured.
Some researchers had tried the immunomagnetic combining flow cytometry technique to
detect CTCs, which had a higher false negative losing amount of target cells. This technique
cost expensive and not brief enough to apply in clinical.
It was common to meet the problem in clinical that it was hard to distinguish the tumor from
inflammation by imaging, while we found that there were no more than two CTCs in stage I.
Budd et al. [35] proposed that it was more accurately to evaluate the development of disease
by CTCs detection than imaging. Both tissue biopsy and marrow biopsy were traumatic, but
CTCs detection by multiparameter flow cytomety was atraumatic that can be achieved in
clinical. Above all, multiparameter flow cytometry was the appropriate technique for the
detection of CTCs to monitor the progression of breast cancer.
We demonstrated that the retrospective study to confirm the CTCs detection by multipara‐
meter flow cytometry technique was a value method to apply in clinical. It suggested the
patients who had CTCs ≥5 prompting a poorer median overall survival (65.5 weeks vs. 95
weeks; P < 0.05). We also found that the prognosis of the breast cancer was related with CTCs
level, age and metastasis but not the clinical pathology and diameter of tumor. Cristofanilli et
al. [36] also proposed that the patients with ≥5 CTCs/7.5 ml common had poorer prognosis
compared with patients with <5 CTCs. CTCs detection by multiparameter flow cytometry
should be a significant method for the evaluation of development and prognosis of cancer,
and it also helped to estimate the treatment of target therapy for patients.
4.2. The significances of CTSCs in breast cancer
We chose CD44+CD24- as an excellent marker in CTSCs identify. CD44+CD24- had been
considered as the marker of CSC [17, 37]. While CD133 was much more restricted in expression
compared with CD44 that was the reason we did not chose CD133 as the CTSCs marker [38–
40]. ALDH1 was another maker to identify CSC from BC. Ginestier et al. reported that the
expression of ALDH1 in normal and breast cancer was 3–10%, while expression of
CD44+CD24- was 31% in contrast [41, 42]. In summary, CD44+CD24- was an excellent maker in
CSC identify.
CTCs may exist after mastectomy and chemotherapy; even there was no clinical manifestation
of breast cancer. It was explained as the theory of “dormancy” in tumor cells [43]. And it was
a part of tumor stem cells. Once the balance between proliferation and apoptosis was destroyed
by some inducement, the disease progressed. The immune system and angiogenesis was
reported, which were correlated closely with tumor cell dormancy [43, 44]. When the tumor
stem cells fell off the primary tumor, they came into the peripheral circle and became the
circulating tumor stem cells (CTSCs).
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We successfully confirmed that the existence of CTSCs and also reveal the relationship between
CTSCs level and different TNM stages. The correlation of CTSCs and clinical pathologic
features remains unclear before. Previous study had reported that the CD44+CD24- cancer stem
cells was not correlated with clinical features such as lymph node status, tumor size, histology
grade, ER, and PR, or HER‐2 [45, 46].
It was reported that the patients who had high expression of CD44+CD24- tumor stem cells
were related with distant metastasis, particularly osseous [45]. And we found the expression
of CTSCs was quite related with RLNM status. It was a novel way for treatment targeting at
CTSCs to prevent metastasis and to evaluate the prognosis.
Cancer stem cells (CSCs) had been confirmed existed in many kinds of epithelial malignancy
[47]. And the CSCs were considered as a subpopulation of tumor cells [48]. The mutation of
normal stem cells resulted in the genesis of CSCs, which had been demonstrated by Cariati
and Purushotham [49]. Therefore, CTSCs were suggested that it was generated not only from
CTCs but also from normal stem cells. Further researches needed to be performed to confirm
it.
Detection of CTCs and CTSCs by using multiparameter flow cytometry was considered as an
effective technique on monitoring disease development and evaluating prognosis [50, 51].
Using multiparameter flow cytometry to detect CTC and CTSC in peripheral blood may
provide new opportunities for the early diagnosis of invasive breast cancer, guide us to select
optimal therapeutic regimens and help us to predict the prognosis. Moreover, we wish to
isolate the CTSCs that have the marker of CD44+CD24-ESA- expressing. Further researches on
CTSCs needed to be demonstrated and we have established a firm basis for following research.
5. Conclusion
Detection of CTCs by using multiparameter flow cytometry was effective and it has the
potential to be a valuable method for both prognosis assessment and cancer research in breast
cancer.
6. Looking forward
There is no doubt that CTCs would become an important test in clinical in near future. The
challenge of the achievement contains the heterogeneity of CTCs and big database of clinical
on CTCs. The heterogeneity of CTCs reflected in different tumor related proteins and mor‐
phology. However, researchers have pay more and more interesting on EMT phenotype that
is common in all kinds of tumors. It will make CTCs detection accessible by decipherment of
conundrums underlying EMT phenotype.
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